Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IgNova Files Patent Application on Antibody Against COVID-19
Details : The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova's technology offers a safe, economical, and unlimited source of polyclonal antibodies...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IGN-ES001
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 20, 2017
Lead Product(s) : IGN-ES001
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Scope International AG | Klinar CRO | CenTrial | Pharmasolutions4U | idv Data Analysis
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
